Jing-Ke Weng

This inventor holds 8 USPTO granted patents and 7 published patent applications. Top assignee: Whitehead Institute for Biomedical Research. Active years: 2021-2025.

USPTO Granted Patents = 8 (Patent Applications = 7)

% Patents Active = 100.0

Average Co-Inventor Count = 2.1

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

8 out of 317

Whitehead Institute for Biomedical Research

patents

Years Active: 2021-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12385055 - Compositions and methods for production of salidroside, icariside D2, and precursors of salidroside and icariside D2 (2025-08-12),

2. 12241072 - Biosynthetic approach for heterologous production and diversification of bioactive lyciumin cyclic peptides (2025-03-04),

3. 11746364 - Enzymatic synthesis of kavalactones and flavokavains (2023-09-05),

4. 11739354 - Enzymatic synthesis of kavalactones and flavokavains (2023-08-29),

5. 11492636 - Modified bialaphos resistance acetyltransferase compositions and uses thereof (2022-11-08),

6. 11408009 - Host cell expression of 4-hydroxyphenylacetaldehyde synthase for production of salidroside, icariside D2, and precursors (2022-08-09),

7. 11377466 - Analogs of the natural product icariin (2022-07-05),

8. 10941429 - Enzymatic synthesis of kavalactones and flavokavains (2021-03-09),

Title: Innovations and Contributions of Inventor Jing-Ke Weng

Introduction

Jing-Ke Weng is a prominent inventor based in Belmont, MA (US). He has made significant contributions to the field of biomedical research, particularly in the area of biosynthesis and transgenic technologies. With a total of 8 patents, Weng's work has advanced our understanding of bioactive compounds and their production.

Latest Patents

Weng's latest patents include compositions and methods for the production of salidroside, icariside D2, and their precursors. These innovations involve transgenic host cells, vectors, and kits that facilitate the creation of transgenic plants. Notably, some embodiments of his work involve transgenic host cells that express a 4-hydroxyphenylacetaldehyde synthase (4HPAAS) and a tyrosol:UDP-glucose 8-O-glucosyltransferase (T8GT). These advancements are crucial for the biosynthesis of salidroside, icariside D2, tyrosol, and 4-hydroxyphenylacetaldehyde. Additionally, Weng has developed a biosynthetic approach for the heterologous production and diversification of bioactive lyciumin cyclic peptides, which includes methods for producing lyciumin precursor peptides.

Career Highlights

Jing-Ke Weng is affiliated with the Whitehead Institute for Biomedical Research, where he conducts his research. His work has garnered attention for its innovative approaches to biosynthesis and genetic engineering. Weng's contributions have not only advanced scientific knowledge but also opened new avenues for the production of valuable bioactive compounds.

Collaborations

Weng has collaborated with notable colleagues such as Tomás Pluskal and Michael Torrens-Spence. These partnerships have further enriched his research and expanded the impact of his innovations.

Conclusion

Jing-Ke Weng's work exemplifies the intersection of innovation and scientific research. His patents and contributions to the field of biomedical research highlight the importance of transgenic technologies in the production of bioactive compounds. Weng's ongoing efforts continue to inspire advancements in the field.